Labs across Europe are churning out new science. Synthetic biology, gene editing, and AI-driven life sciences are moving fast. But a new European Research Council (ERC) analysis lays bare a tough truth. Most discoveries stall before they ever reach the real world. The main reason? Money dries up and support falls short long before products hit the market.
From 2014 to 2023, the ERC invested €4.09 billion in 2,416 biotech projects across 28 countries. That’s 21% of all ERC research funding in that time. The money went into everything from medical and industrial biotech to agriculture, environmental science, blue biotech, and new fields like engineered living materials and nanotech. Still, most of these breakthroughs never make it to market.
In the ERC biotechnology portfolio, 211 researchers have filed patent applications and 72 spin-off companies have been created, highlighting both progress and the ongoing challenge of market transfer.
Funding gaps and weak ecosystems slow biotech
A May 2026 survey of ERC-funded biotech researchers named five big problems. The top issue is a lack of steady support for cutting-edge research. There’s also a funding hole between early discoveries and the ERC’s own Proof of Concept grants. Commercialisation is tough. Scaling up is even harder. Weak innovation networks and unclear rules make things worse.
One number stands out. About 22% of biotech projects are still far from any practical use. That shows how much the sector depends on long-term investment in basic science. Quick profits are rare. Most projects need years before they can pay off.
AI and gene editing drive the next wave
Researchers see a clear future. By 2030, they expect AI-powered life-science data mining (85%), mRNA vaccines (82%), omics tech (78%), tissue engineering (77%), and CRISPR-Cas (76%) to lead the way. Other likely drivers include CAR-based therapies, synthetic cells, engineered living materials, and pluripotent stem cells.
There are some wins. Since 2014, biotech projects have landed 531 ERC Proof of Concept grants—30% of all such grants. In the same period, 211 researchers filed patents and 72 spin-off companies launched. Another 24 ERC-backed projects secured 25 European Innovation Council Transition grants. Some ideas are finally moving out of the lab.
At the Biospain 2026 conference, a European Commission representative estimated that Europe has mobilized around €25 billion in biotech funding, compared to over €220 billion in the United States. New initiatives such as the Bioeconomy Investment Deployment Group, Scale-up Europe Fund, and the planned European Competitiveness Fund are being developed to address this scale-up gap.
Research grows, but market impact lags
The ERC’s billions have built a strong research base. But turning science into products and real-world impact is still a struggle. This isn’t just a European problem. Other regions face the same roadblocks. The push to turn genomics and AI breakthroughs into new crops shows how hard it is to move from lab to field.
Europe has the talent. It has the ideas. What’s missing is a clear plan to get from discovery to deployment. Without targeted funding for the jump from research to real-world use, and without stronger innovation networks and clear rules, Europe could lose its lead. The risk is real. If these barriers stay in place, biotech breakthroughs will stay stuck in the lab. Patients, industry, and society will miss out.
The latest ERC report puts it plainly. About 22% of biotech projects are nowhere near practical use. The report lists five main barriers: not enough support for frontier research, funding gaps between early work and Proof of Concept, trouble scaling up, weak innovation networks, and unclear rules.
Industry voices at autumn 2026 conferences hammered the same point. Europe’s problem isn’t a lack of ideas. It’s a lack of capital to scale. Fragmented regulation, a weak path to market, and not enough private money all add up. BioXconomy’s analysis of the funding landscape spells it out. The system is broken. The gap is growing.
